- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06140420
Naltrexone for Prolonged Grief Disorder (NPGD)
November 18, 2023 updated by: Jonathan Singer, Texas Tech University
Naltrexone Treatment for Prolonged Grief Disorder: A Proof of Concept Study
This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD).
Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
48
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jonathan D Singer, PhD
- Phone Number: 7757228066
- Email: jonsinge@ttu.edu
Study Contact Backup
- Name: Yasin Ibrahim, MD
- Email: yasin.ibrahim@ttuhsc.edu
Study Locations
-
-
Texas
-
Lubbock, Texas, United States, 79409
- Recruiting
- Texas Tech Health Science Center
-
Contact:
- Jonathan D Singer, PhD
- Phone Number: 775-722-8066
- Email: jonsinge@ttu.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18 years of age or older.
- Lives within a reasonable distance from NYPH for convenient clinic visits.
- Can speak, read, and write English proficiently.
- Meet diagnostic criteria for PGD based on the DSM guidelines
- If a female patient, must agree to use a method of contraception and be willing and able to continue contraception during the first 8 weeks of the study while she is taking the study drug. Female patients who are planning to use oral hormonal contraception during this time must have initiated it at least 2 months prior to the baseline visit.
- If a male patient, must agree to use a method of contraception and be willing and able to continue contraception during the first 8 weeks of the study while he is taking the study drug.
Exclusion Criteria:
• Having recently started taking/prescribed medications for any psychiatric illness (e.g.
SSRIs for MDD) within the past 3 months; participants who have been taking this medication for longer than 3 months can be included.
- Having recently started psychotherapy for any psychiatric illness within the past 3 months; participants who have been receiving psychotherapy for longer than 3 months can be included.
- Prior history of recently active (e.g. within the past 3 months) opioid dependence.
- Current prescription, non-prescription, or illicit opioid use, (i.e., acute use within the past 14 days or chronic use within the last 30 days), including opioid antagonists for alcohol or opioid dependence, all opioid analgesics, certain cough and cold remedies (e.g., codeine), and certain anti-diarrheal preparations (e.g., loperamide).
- Possible future use of opioids during the study (e.g. for surgery).
- Current use of leflunomide (Arava), droperidol (Droleptan), diazepam (Valium), thioridazine (Mellaril, Novoridazine, Thioril), or any other clinically relevant medication that has potential to cause liver injury with concurrent use of naltrexone.
- Currently pregnant, lactating, or planning to become pregnant during the study.
- Active hepatitis or liver disease.
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels more than one standard deviation (SD) above the upper limit of normal on initial laboratory examination. Screen positive for active suicidal thoughts or behaviors.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Comparator: Placebo
24 randomized patients will take placebo daily for 8 weeks.
|
Oral Placebo
|
Active Comparator: Active Comparator: Naltrexone
24 randomized patients will take naltrexone daily for 8 weeks
|
Generic, oral tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Prolonged Grief Disorder symptom severity as assessed by the PGD-12
Time Frame: Weekly for 12 weeks
|
Change in PGD symptom severity will be measured by using Prolonged Grief-13 (PGD-12), a self-rated scale consisting of 12 items.
For this study, we have added an additional item inquiring about loneliness to be congruent with DSM-5-TR criteria and SCIP.
This 5-point Likert-type of measurement tool evaluates the intensity and severity of the PGD.
The validity and reliability of the PGD-12 was tested and validated in previous studies.
|
Weekly for 12 weeks
|
Change in Prolonged Grief Disorder severity as assessed by Structured Clinical Interview for PGD
Time Frame: Every 4 weeks for 8 weeks
|
The IOS is a self-reported pictorial tool use to measure the subjectively perceived closeness of a relationship.
The tool asks respondents to select one of seven pairs of increasingly overlapping circles that best represents their relationship with another, with more overlap signifying a closer relationship.
This scale possesses good reliability, with (α = .93)
for the entire sample, (α = .87)
for family, (α = .92)
for friendship, and (α = .95)
for romantic relationships.
Test-retest reliability shows similar findings, with (α = .83)
for the entire sample, (α = .85)
for family, (α = .86)
for friendship, and (α = .85)
for romantic relationships.
|
Every 4 weeks for 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in strength of subjectively perceived closeness of a social relationship as measured by the Inclusion of the other in the Self (IOS) Scale
Time Frame: Every 4 weeks for 12 weeks
|
The IOS is a self-reported pictorial tool use to measure the subjectively perceived closeness of a relationship.
The tool asks respondents to select one of seven pairs of increasingly overlapping circles that best represents their relationship with another, with more overlap signifying a closer relationship.
This scale possesses good reliability, with (α = .93)
for the entire sample, (α = .87)
for family, (α = .92)
for friendship, and (α = .95)
for romantic relationships.
Test-retest reliability shows similar findings, with (α = .83)
for the entire sample, (α = .85)
for family, (α = .86)
for friendship, and (α = .85)
for romantic relationships.
|
Every 4 weeks for 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Gang J, Kocsis J, Avery J, Maciejewski PK, Prigerson HG. Naltrexone treatment for prolonged grief disorder: study protocol for a randomized, triple-blinded, placebo-controlled trial. Trials. 2021 Feb 1;22(1):110. doi: 10.1186/s13063-021-05044-8.
- Kakarala SE, Roberts KE, Rogers M, Coats T, Falzarano F, Gang J, Chilov M, Avery J, Maciejewski PK, Lichtenthal WG, Prigerson HG. The neurobiological reward system in Prolonged Grief Disorder (PGD): A systematic review. Psychiatry Res Neuroimaging. 2020 Sep 30;303:111135. doi: 10.1016/j.pscychresns.2020.111135. Epub 2020 Jul 3.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2023
Primary Completion (Estimated)
July 1, 2025
Study Completion (Estimated)
July 1, 2025
Study Registration Dates
First Submitted
November 14, 2023
First Submitted That Met QC Criteria
November 14, 2023
First Posted (Actual)
November 20, 2023
Study Record Updates
Last Update Posted (Estimated)
November 21, 2023
Last Update Submitted That Met QC Criteria
November 18, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TexasTechU6
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Placebo
-
King Faisal Specialist Hospital & Research CenterCompletedPlacebo Effect | Placebo Drug InteractionSaudi Arabia
-
VA Office of Research and DevelopmentActive, not recruitingActive Ethanol and Active Iomazenil | Active Ethanol and Placebo Iomazenil | Placebo Ethanol and Placebo Iomazenil | Placebo Ethanol and Active Iomazenil | Driving Under the Influence | Alcohol Impairment | Alcohol EffectUnited States
-
King Faisal Specialist Hospital & Research CenterKing AbdulAziz City for Science and TechnologyCompletedPlacebo Effect | Placebo Mechanisms of ActionSaudi Arabia
-
National Taiwan Sport UniversityCompleted
-
Hartford HospitalCompletedTreatment | PlaceboUnited States
-
Harvard School of Public Health (HSPH)Brigham and Women's HospitalCompleted
-
University of OttawaRecruiting
-
San Diego State UniversityRecruitingPlacebo | NaltrexoneUnited States
-
University of Colorado, DenverCompleted
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States